{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T19:29:53Z","timestamp":1792265393717,"version":"4.4.0"},"reference-count":184,"publisher":"MDPI AG","issue":"20","license":[{"start":{"date-parts":[[2024,10,12]],"date-time":"2024-10-12T00:00:00Z","timestamp":1728691200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Amiodarone, a bi-iodinated benzofuran derivative, is among the most commonly used antiarrhythmic drugs due to its high level of effectiveness. Though initially categorized as a class III agent, amiodarone exhibits antiarrhythmic properties across all four classes of antiarrhythmic drugs. Amiodarone is highly effective in maintaining sinus rhythm in patients with paroxysmal atrial fibrillation while also playing a crucial role in preventing a range of ventricular arrhythmias. Amiodarone has a complex pharmacokinetic profile, characterized by a large volume of distribution and a long half-life, which can range from several weeks to months, resulting in prolonged effects even after discontinuation. Side effects may include thyroid dysfunction, pulmonary fibrosis, and hepatic injury, necessitating regular follow-ups. Additionally, amiodarone interacts with several drugs, including anticoagulants, which must be managed to prevent adverse effects. Therefore, a deep understanding of both oral and intravenous formulations, as well as proper dosage adjustments, is essential. The aim of this paper is to provide a comprehensive and updated review on amiodarone\u2019s indications, contraindications, recommended dosages, drug interactions, side effects, and monitoring protocols.<\/jats:p>","DOI":"10.3390\/jcm13206094","type":"journal-article","created":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T12:44:31Z","timestamp":1728909871000},"page":"6094","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["Amiodarone Therapy: Updated Practical Insights"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1721-2360","authenticated-orcid":false,"given":"Victori\u021ba","family":"\u0218orodoc","sequence":"first","affiliation":[{"name":"Faculty of Medicine, Grigore T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania"},{"name":"Second Internal Medicine Department, Sf. Spiridon Clinical Emergency Hospital, 700111 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Indrei","sequence":"additional","affiliation":[{"name":"Radiology and Medical Imaging Department, Sf. Spiridon Clinical Emergency Hospital, 700111 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-7850-8871","authenticated-orcid":false,"given":"Catinca","family":"Dobroghii","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Grigore T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5567-8746","authenticated-orcid":false,"given":"Andreea","family":"Asaftei","sequence":"additional","affiliation":[{"name":"Second Internal Medicine Department, Sf. Spiridon Clinical Emergency Hospital, 700111 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0043-9051","authenticated-orcid":false,"given":"Alexandr","family":"Ceasovschih","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Grigore T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania"},{"name":"Second Internal Medicine Department, Sf. Spiridon Clinical Emergency Hospital, 700111 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-6884-1524","authenticated-orcid":false,"given":"Mihai","family":"Constantin","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Grigore T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania"},{"name":"Second Internal Medicine Department, Sf. Spiridon Clinical Emergency Hospital, 700111 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0525-0645","authenticated-orcid":false,"given":"C\u0103t\u0103lina","family":"Lionte","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Grigore T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania"},{"name":"Second Internal Medicine Department, Sf. Spiridon Clinical Emergency Hospital, 700111 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca Codrina","family":"Mor\u0103ra\u0219u","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Grigore T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania"},{"name":"Second Internal Medicine Department, Sf. Spiridon Clinical Emergency Hospital, 700111 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra-Diana","family":"Diaconu","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Grigore T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania"},{"name":"Second Internal Medicine Department, Sf. Spiridon Clinical Emergency Hospital, 700111 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren\u021biu","family":"\u0218orodoc","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Grigore T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania"},{"name":"Second Internal Medicine Department, Sf. Spiridon Clinical Emergency Hospital, 700111 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,10,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s40256-020-00401-5","article-title":"Amiodarone: A Comprehensive Guide for Clinicians","volume":"20","author":"Hamilton","year":"2020","journal-title":"Am. J. Cardiovasc. Drugs."},{"key":"ref_2","unstructured":"Bhatt, D.L., and Opie, L.H. (2021). Opie\u2019s Cardiovascular Drugs: A Companion to Braunwald\u2019s Heart Disease, Elsevier."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1002\/j.1552-4604.1991.tb03673.x","article-title":"Pharmacology and Pharmacokinetics of Amiodarone","volume":"31","author":"Freedman","year":"1991","journal-title":"J. Clin. Pharmacol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1002\/bdd.457","article-title":"Pharmacokinetics of Amiodarone in Hyperlipidemic and Simulated High Fat-Meal Rat Models","volume":"26","author":"Shayeganpour","year":"2005","journal-title":"Biopharm. Drug. Dispos."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Shleghm, M.R., Mircioiu, C., Voicu, V.A., Mircioiu, I., and Anuta, V. (2021). Estimation of the in Vivo Release of Amiodarone from the Pharmacokinetics of Its Active Metabolite and Correlation with Its in Vitro Release. Front. Pharmacol., 11.","DOI":"10.3389\/fphar.2020.621667"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1001\/jama.298.11.1312","article-title":"Prescribing Amiodarone","volume":"298","author":"Vassallo","year":"2007","journal-title":"JAMA"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1161\/01.CIR.100.19.2025","article-title":"Evidence-Based Analysis of Amiodarone Efficacy and Safety","volume":"100","author":"Connolly","year":"1999","journal-title":"Circulation"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1067\/mcp.2000.107047","article-title":"Population Pharmacokinetics of Long-Term Oral Amiodarone Therapy","volume":"67","author":"Pollak","year":"2000","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Gelman, I., Sharma, N., Mckeeman, O., Lee, P., Campagna, N., Tomei, N., Baranchuk, A., Zhang, S., and El-Diasty, M. (2024). The Ion Channel Basis of Pharmacological Effects of Amiodarone on Myocardial Electrophysiological Properties, a Comprehensive Review. Biomed. Pharmacother, 174.","DOI":"10.1016\/j.biopha.2024.116513"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/S0735-1097(84)80367-8","article-title":"Amiodarone: Electrophysiologic Actions, Pharmacokinetics and Clinical Effects","volume":"3","author":"Zipes","year":"1984","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/j.1600-0773.1990.tb00694.x","article-title":"Class III Antiarrhythmic Action Linked with Positive Inotropy: Acute Electrophysiological and Inotropic Effects of Amiodarone in Vitro","volume":"66","author":"Tande","year":"1990","journal-title":"Pharmacol. Toxicol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1177\/106002809603000612","article-title":"Intravenous Amiodarone: Pharmacology, Pharmacokinetics, and Clinical Use","volume":"30","author":"Chow","year":"1996","journal-title":"Ann. Pharmacother."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Ghovanloo, M.-R., Abdelsayed, M., and Ruben, P.C. (2016). Effects of Amiodarone and N-Desethylamiodarone on Cardiac Voltage-Gated Sodium Channels. Front. Pharmacol., 7.","DOI":"10.3389\/fphar.2016.00039"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0008-6363(97)00114-4","article-title":"Cellular Electropharmacology of Amiodarone","volume":"35","author":"Kodama","year":"1997","journal-title":"Cardiovasc. Res."},{"key":"ref_15","first-page":"e12895","article-title":"QT Dispersion and Drug-Induced Torsade de Pointes","volume":"13","author":"Friedman","year":"2021","journal-title":"Cureus"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1001\/archinte.160.12.1741","article-title":"Practical Guidelines for Clinicians Who Treat Patients with Amiodarone","volume":"160","author":"Goldschlager","year":"2000","journal-title":"Arch. Intern. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/0033-0620(89)90017-0","article-title":"Amiodarone and Thyroid Function","volume":"31","author":"Nademanee","year":"1989","journal-title":"Prog. Cardiovasc. Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1210\/clinem\/dgaa686","article-title":"Evaluation and Treatment of Amiodarone-Induced Thyroid Disorders","volume":"106","author":"Ylli","year":"2020","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e740","DOI":"10.1161\/CIR.0000000000000613","article-title":"2018 American Heart Association Focused Update on Advanced Cardiovascular Life Support Use of Antiarrhythmic Drugs during and Immediately after Cardiac Arrest: An Update to the American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care","volume":"138","author":"Panchal","year":"2018","journal-title":"Circulation"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1093\/eurheartj\/ehac262","article-title":"2022 ESC Guidelines for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death","volume":"43","author":"Zeppenfeld","year":"2022","journal-title":"Eur. Heart J."},{"key":"ref_21","first-page":"ehae176","article-title":"2024 ESC Guidelines for the Management of Atrial Fibrillation Developed in Collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"45","author":"Van","year":"2024","journal-title":"Eur. Heart J."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e91","DOI":"10.1016\/j.jacc.2017.10.054","article-title":"2017 AHA\/ACC\/HRS Guideline for Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death","volume":"72","author":"Stevenson","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1016\/S0140-6736(20)32338-2","article-title":"Advanced Reperfusion Strategies for Patients with Out-of-Hospital Cardiac Arrest and Refractory Ventricular Fibrillation (ARREST): A Phase 2, Single Centre, Open-Label, Randomised Controlled Trial","volume":"396","author":"Yannopoulos","year":"2020","journal-title":"Lancet"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1056\/NEJM199909163411203","article-title":"Amiodarone for Resuscitation after Out-of-Hospital Cardiac Arrest due to Ventricular Fibrillation","volume":"341","author":"Kudenchuk","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMoa1514204","article-title":"Amiodarone, Lidocaine, or Placebo in Out-of-Hospital Cardiac Arrest","volume":"374","author":"Kudenchuk","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e257","DOI":"10.1097\/MJT.0000000000000918","article-title":"Update in Electrical Storm Therapy","volume":"26","author":"Cozma","year":"2019","journal-title":"Am. J. Ther."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"ehw230","DOI":"10.1093\/eurheartj\/ehw230","article-title":"Randomized Comparison of Intravenous Procainamide vs. Intravenous Amiodarone for the Acute Treatment of Tolerated Wide QRS Tachycardia: The PROCAMIO Study","volume":"38","author":"Ortiz","year":"2016","journal-title":"Eur. Heart J."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1093\/europace\/euy310","article-title":"Pre- and Post-Treatment with Amiodarone for Elective Electrical Cardioversion of Atrial Fibrillation: A Systematic Review and Meta-Analysis","volume":"21","author":"Um","year":"2019","journal-title":"Europace"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1097\/00003246-200106000-00011","article-title":"Amiodarone versus Diltiazem for Rate Control in Critically Ill Patients with Atrial Tachyarrhythmias","volume":"29","author":"Geppert","year":"2001","journal-title":"Crit. Care Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1093\/eurheartj\/ehz467","article-title":"2019 ESC Guidelines for the Management of Patients with Supraventricular Tachycardia The Task Force for the Management of Patients with Supraventricular Tachycardia of the European Society of Cardiology (ESC)","volume":"41","author":"Brugada","year":"2019","journal-title":"Eur. Heart J."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1513614","article-title":"Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs","volume":"375","author":"Sapp","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_32","first-page":"CD005049","article-title":"Antiarrhythmics for Maintaining Sinus Rhythm after Cardioversion of Atrial Fibrillation","volume":"3","author":"Valembois","year":"2015","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_33","first-page":"CD005049","article-title":"Antiarrhythmics for Maintaining Sinus Rhythm after Cardioversion of Atrial Fibrillation","volume":"9","author":"Valembois","year":"2019","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1111\/jce.12535","article-title":"Efficacy of Amiodarone in Patients with Atrial Fibrillation with and without Left Ventricular Dysfunction: A Pooled Analysis of AFFIRM and AF-CHF Trials","volume":"25","author":"Wyse","year":"2014","journal-title":"J. Cardiovasc. Electrophysiol."},{"key":"ref_35","first-page":"e007955","article-title":"Drug Interactions Affecting Antiarrhythmic Drug Use","volume":"15","author":"Mar","year":"2022","journal-title":"Circ. Arrhythm. Electrophysiol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/S0735-1097(86)80234-0","article-title":"Rodolphe Ruffy Flecainide and Amiodarone Interaction","volume":"7","author":"Shea","year":"1986","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1016\/S0002-9149(03)00395-3","article-title":"Safety and Feasibility of a Clinical Pathway for the Outpatient Initiation of Antiarrhythmic Medications in Patients with Atrial Fibrillation or Atrial Flutter","volume":"91","author":"Hauser","year":"2003","journal-title":"Am. J. Card."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1093\/toxsci\/kfs307","article-title":"Interaction of Digitalis-like Compounds with P-Glycoprotein","volume":"131","author":"Gozalpour","year":"2012","journal-title":"Toxicol. Sci."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/clpt.2008.195","article-title":"Drug\u2013Drug Interactions Mediated through P-Glycoprotein: Clinical Relevance and in Vitro\u2013in Vivo Correlation Using Digoxin as a Probe Drug","volume":"85","author":"Fenner","year":"2008","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) Collaborative Group, Armitage, J., Bowman, L., Wallendszus, K., Bulbulia, R., Rahimi, K., Haynes, R., Parish, S., Peto, R., and Collins, R. (2010). Intensive Lowering of LDL Cholesterol with 80 Mg versus 20 Mg Simvastatin Daily in 12,064 Survivors of Myocardial Infarction: A Double-Blind Randomised Trial. Lancet, 376, 1658\u20131669.","DOI":"10.1016\/S0140-6736(10)60310-8"},{"key":"ref_41","first-page":"134","article-title":"Concomitant Use of Simvastatin and Amiodarone Resulting in Severe Rhabdomyolysis: A Case Report and Review of the Literature","volume":"66","author":"Marot","year":"2011","journal-title":"Acta Clin. Belg."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/sj.clpt.6100098","article-title":"Amiodarone Interacts with Simvastatin but Not with Pravastatin Disposition Kinetics","volume":"81","author":"Becquemont","year":"2007","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1111\/jth.13614","article-title":"The Effect of Amiodarone on Warfarin Anticoagulation: A Register-Based Nationwide Cohort Study Involving the Swedish Population","volume":"15","author":"Holm","year":"2017","journal-title":"J. Thromb. Haemost."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.amjcard.2022.10.031","article-title":"Association between Concurrent Use of Amiodarone and DOACs and Risk of Bleeding in Patients with Atrial Fibrillation","volume":"186","author":"Shurrab","year":"2023","journal-title":"Am. J. Cardiol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.jfma.2023.02.012","article-title":"Impact of Amiodarone on Plasma Concentration of Direct Oral Anticoagulant in Patients with Atrial Fibrillation","volume":"122","author":"Lin","year":"2023","journal-title":"J. Formos. Med. Assoc."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.cjco.2021.11.002","article-title":"Amiodarone, Verapamil, or Diltiazem Use with Direct Oral Anticoagulants and the Risk of Hemorrhage in Older Adults","volume":"4","author":"Hill","year":"2022","journal-title":"CJC Open"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1093\/europace\/euab065","article-title":"2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation","volume":"23","author":"Steffel","year":"2021","journal-title":"Europace"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","article-title":"2023 Focused Update of the 2021 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure","volume":"44","author":"McDonagh","year":"2023","journal-title":"Eur. Heart J."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1161\/CIRCULATIONAHA.121.057237","article-title":"Empagliflozin Reverses Late Na + Current Enhancement and Cardiomyocyte Proarrhythmia in a Translational Murine Model of Heart Failure with Preserved Ejection Fraction","volume":"145","author":"Hegyi","year":"2022","journal-title":"Circulation"},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Kolesnik, E., Scherr, D., Rohrer, U., Benedikt, M., Manninger, M., Sourij, H., and von Lewinski, D. (2022). SGLT2 Inhibitors and Their Antiarrhythmic Properties. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23031678"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s12933-019-0984-0","article-title":"Sodium-Glucose Co-Transporter 2 Inhibition as a Mitochondrial Therapy for Atrial Fibrillation in Patients with Diabetes?","volume":"19","author":"Yurista","year":"2020","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Jhuo, S.-J., Liu, I.-H., Tsai, W.-C., Chou, T.-W., Lin, Y.-H., Wu, B.-N., Lee, K.-T., and Lai, W.-T. (2020). Effects of Secretome from Fat Tissues on Ion Currents of Cardiomyocyte Modulated by Sodium-Glucose Transporter 2 Inhibitor. Molecules, 25.","DOI":"10.3390\/molecules25163606"},{"key":"ref_53","first-page":"1","article-title":"Empagliflozin in Paroxysmal or Persistent Atrial Fibrillation: A Possible Antiarrhythmic Effect","volume":"7","author":"Fazio","year":"2021","journal-title":"Diabetes Updates"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1055\/s-2008-1068613","article-title":"Acceleration of Amiodarone Elimination by Cholestyramine","volume":"111","author":"Nitsch","year":"1986","journal-title":"Dtsch. Med. Wochenschr."},{"key":"ref_55","first-page":"100155","article-title":"Approach to Amiodarone Induced Thyroid Storm: A Case Report","volume":"30","author":"Freeman","year":"2023","journal-title":"J. Clin. Transl. Endocrinol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1177\/106002809302700506","article-title":"Cyclosporine-Amiodarone Interaction","volume":"27","author":"Chitwood","year":"1993","journal-title":"Ann. Pharmacother."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Filosto, M., Piccinelli, S.C., Pichiecchio, A., Musumeci, O., Galvagni, A., Caria, F., Gallo Cassarino, S., Baldelli, E., Vitale, R., and Padovani, A. (2019). Late and Severe Myopathy in a Patient with Glycogenosis VII Worsened by Cyclosporine and Amiodarone. Front. Neurol., 10.","DOI":"10.3389\/fneur.2019.00077"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1080\/17425255.2019.1604685","article-title":"Pharmacokinetics and Pharmacodynamics of Cytochrome P450 Inhibitors for HIV Treatment","volume":"15","author":"Gong","year":"2019","journal-title":"Expert. Opin. Drug. Metab. Toxicol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"329","DOI":"10.3851\/IMP2715","article-title":"Amiodarone and Concurrent Antiretroviral Therapy: A Case Report and Review of the Literature","volume":"19","author":"Naccarato","year":"2013","journal-title":"Antivir. Ther."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1007\/s40262-019-00764-2","article-title":"Clinical Pharmacokinetics and Pharmacodynamics of Rifampicin in Human Tuberculosis","volume":"58","author":"Abulfathi","year":"2019","journal-title":"Clin. Pharmacokinet."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1097\/FTD.0000000000000487","article-title":"Amiodarone Rifampicin Drug\u2013Drug Interaction Management with Therapeutic Drug Monitoring","volume":"40","author":"Demmer","year":"2018","journal-title":"Ther. Drug Monit."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ajem.2024.01.010","article-title":"GLP-1 Agonists: A Review for Emergency Clinicians","volume":"78","author":"Long","year":"2024","journal-title":"Am. J. Emerg. Med."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1161\/CIRCULATIONAHA.122.059595","article-title":"GLP-1 Receptor Agonists for the Reduction of Atherosclerotic Cardiovascular Risk in Patients with Type 2 Diabetes","volume":"146","author":"Marx","year":"2022","journal-title":"Circulation"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"100917","DOI":"10.1016\/j.jpha.2023.12.007","article-title":"GLP-1 Receptor Agonists and Myocardial Metabolism in Atrial Fibrillation","volume":"14","author":"Zhong","year":"2024","journal-title":"J. Pharm. Anal."},{"key":"ref_65","first-page":"922","article-title":"Glucagon-like Peptide-1 Protects against Atrial Fibrillation and Atrial Remodeling in Type 2 Diabetic Mice","volume":"8","author":"Bohne","year":"2023","journal-title":"J. Am. Coll. Cardiol. Basic Trans. Sci."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"3749","DOI":"10.1007\/s12325-024-02959-x","article-title":"Effects of Glucagon-like Peptide 1 Receptor Agonists on Atrial Fibrillation Recurrence after Catheter Ablation: A Systematic Review and Meta-Analysis","volume":"41","author":"Karakasis","year":"2024","journal-title":"Adv. Ther."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1007\/s11695-008-9415-0","article-title":"Amiodarone-Induced Hyperthyroidism during Massive Weight Loss Following Gastric Bypass","volume":"17","author":"Bourron","year":"2007","journal-title":"Obes. Surg."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s40264-023-01392-3","article-title":"Drug-Drug Interactions between Glucagon-like Peptide 1 Receptor Agonists and Oral Medications: A Systematic Review","volume":"47","author":"Calvarysky","year":"2024","journal-title":"Drug Saf."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1161\/CIRCULATIONAHA.121.055783","article-title":"Polymorphic Ventricular Tachycardia: Terminology, Mechanism, Diagnosis, and Emergency Therapy","volume":"144","author":"Viskin","year":"2021","journal-title":"Circulation"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"210","DOI":"10.2174\/1574884713666180223123947","article-title":"Drug-Induced QT Interval Prolongation in the Intensive Care Unit","volume":"12","author":"Etchegoyen","year":"2018","journal-title":"Curr. Clin. Pharmacol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1007\/s11606-019-05477-7","article-title":"Measurement and Management of QT Interval Prolongation for General Physicians","volume":"35","author":"Indraratna","year":"2019","journal-title":"J. Gen. Intern. Med."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1016\/j.amjcard.2019.02.057","article-title":"Comparison of QT Interval Measurement Methods and Correction Formulas in Atrial Fibrillation","volume":"123","author":"Tooley","year":"2019","journal-title":"Am. J. Card."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"C118","DOI":"10.1016\/j.jacc.2017.07.418","article-title":"GW28-E0546 QT Measurement in the Presence of Atrial Fibrillation: Minimizing the Effects of RR Fluctuations on QT Interval","volume":"70","author":"Wang","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"e273","DOI":"10.1161\/CIR.0000000000000527","article-title":"Update to Practice Standards for Electrocardiographic Monitoring in Hospital Settings: A Scientific Statement from the American Heart Association","volume":"136","author":"Sandau","year":"2017","journal-title":"Circulation"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.hrthm.2006.05.023","article-title":"Bazett and Fridericia QT Correction Formulas Interfere with Measurement of Drug-Induced Changes in QT Interval","volume":"3","author":"Indik","year":"2006","journal-title":"Heart Rhythm"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jelectrocard.2004.08.030","article-title":"A Comparison of Commonly Used QT Correction Formulae: The Effect of Heart Rate on the QTc of Normal ECGs","volume":"37","author":"Luo","year":"2004","journal-title":"J. Electrocardiol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.jelectrocard.2013.03.007","article-title":"Prevalence and Prognostic Significance of Long QT Interval among Patients with Chest Pain: Selecting an Optimum QT Rate Correction Formula","volume":"46","author":"Hasanien","year":"2013","journal-title":"J. Electrocardiol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1007\/s00063-015-0071-6","article-title":"Life-Threatening Cardiac Arrhythmias due to Drug-Induced QT Prolongation","volume":"111","author":"Michels","year":"2015","journal-title":"Med. Klin. Intensivmed."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1159\/000338345","article-title":"Predicting Torsade de Pointes in Acquired Long QT Syndrome: Optimal Identification of Critical QT Interval Prolongation","volume":"122","author":"Chiladakis","year":"2012","journal-title":"Cardiology"},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Chen, Y., Guo, X., Sun, G., Li, Z., Zheng, L., and Sun, Y. (2018). Effect of Serum Electrolytes within Normal Ranges on QTc Prolongation: A Cross-Sectional Study in a Chinese Rural General Population. BMC Cardiovasc. Dis., 18.","DOI":"10.1186\/s12872-018-0906-1"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s13256-021-03204-7","article-title":"Vomiting, Electrolyte Disturbance, and Medications; the Perfect Storm for Acquired Long QT Syndrome and Cardiac Arrest: A Case Report","volume":"16","author":"Tiver","year":"2022","journal-title":"J. Med. Case Rep."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1016\/j.amjcard.2019.09.008","article-title":"Meta-Analysis Comparing the Relative Risk of Adverse Events for Amiodarone versus Placebo","volume":"124","author":"Ruzieh","year":"2019","journal-title":"Am. J. Cardiol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"e311","DOI":"10.1016\/j.jemermed.2010.07.024","article-title":"Amiodarone-Induced Acute Respiratory Distress Syndrome Masquerading as Acute Heart Failure","volume":"43","author":"Kumar","year":"2012","journal-title":"J. Emerg. Med."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1136\/pgmj.2005.040105","article-title":"Amiodarone Toxicity Presenting as Pulmonary Mass and Peripheral Neuropathy: The Continuing Diagnostic Challenge","volume":"82","author":"Azzam","year":"2006","journal-title":"Postgrad. Med. J."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/S0953-6205(01)00127-3","article-title":"Pulmonary Mass and Multiple Lung Nodules Mimicking a Lung Neoplasm as Amiodarone-Induced Pulmonary Toxicity","volume":"12","author":"Ballesta","year":"2001","journal-title":"Eur. J. Intern. Med."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1378\/chest.92.1.179","article-title":"Amiodarone Pulmonary Toxicity Presenting as Bilateral Exudative Pleural Effusions","volume":"92","author":"Hannan","year":"1987","journal-title":"Chest"},{"key":"ref_87","first-page":"100974","article-title":"Amiodarone-Induced Pulmonary Toxicity with an Excellent Response to Treatment: A Case Report","volume":"29","author":"Terzo","year":"2020","journal-title":"Respir. Med. Case Rep."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s00392-010-0181-3","article-title":"Amiodarone-Induced Pulmonary Toxicity: An Under-Recognized and Severe Adverse Effect?","volume":"99","author":"Schwaiblmair","year":"2010","journal-title":"Clin. Res. Cardiol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"539","DOI":"10.2165\/11532320-000000000-00000","article-title":"Amiodarone","volume":"33","author":"Papiris","year":"2010","journal-title":"Drug Saf."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.amsu.2017.07.034","article-title":"Rapid Onset of Amiodarone Induced Pulmonary Toxicity after Lung Lobe Resection\u2014A Case Report and Review of Recent Literature","volume":"21","author":"Baumann","year":"2017","journal-title":"Ann. Med. Surg."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.amjms.2016.08.013","article-title":"Acute Amiodarone Pulmonary Toxicity after Surgical Procedures","volume":"352","author":"Teerakanok","year":"2016","journal-title":"Am. J. Med. Sci."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"A1541","DOI":"10.1016\/j.chest.2023.07.1057","article-title":"Amiodarone-Induced Pulmonary Toxicity Leading to Acute Respiratory Distress Syndrome","volume":"164","author":"Melendez","year":"2023","journal-title":"Chest"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1093\/qjmed\/hcz096","article-title":"Amiodarone Toxicity and the Acute Respiratory Distress Syndrome","volume":"112","author":"Sharma","year":"2019","journal-title":"QJM"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"e01165","DOI":"10.1002\/rcr2.1165","article-title":"Variable Radiographic and Histologic Presentations of Amiodarone-Related Interstitial Lung Disease and the Importance of Avoiding Re-Exposure","volume":"11","author":"Tsai","year":"2023","journal-title":"Respirol. Case Rep."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1155\/2009\/282540","article-title":"Amiodarone Pulmonary Toxicity","volume":"16","author":"Wolkove","year":"2009","journal-title":"Can. Respir. J."},{"key":"ref_96","first-page":"252","article-title":"Regulation of Macroautophagy in Amiodarone-Induced Pulmonary Fibrosis","volume":"1","author":"Mahavadi","year":"2015","journal-title":"J. Pathol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"61","DOI":"10.4997\/jrcpe.2021.115","article-title":"Amiodarone Lung: Under Recognised but Not Forgotten","volume":"51","author":"Baron","year":"2021","journal-title":"J. R. Coll. Physicians Edinb."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1177\/1753465809348015","article-title":"Reduction of Amiodarone Pulmonary Toxicity in Patients Treated with Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers","volume":"3","author":"Kosseifi","year":"2009","journal-title":"Ther. Adv. Resp. Dis."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/01.JAA.0000524713.17719.c8","article-title":"Amiodarone-Induced Pulmonary Toxicity","volume":"30","author":"Colby","year":"2017","journal-title":"JAAPA"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.2169\/internalmedicine.39.1097","article-title":"Serum KL-6 as a possible marker for amiodarone-induced pulmonary toxicity","volume":"39","author":"Nakajima","year":"2000","journal-title":"Intern. Med."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"4724","DOI":"10.21037\/jtd.2018.07.54","article-title":"Diagnostic Value of KL-6 in Idiopathic Interstitial Pneumonia","volume":"10","author":"Zheng","year":"2018","journal-title":"J. Thorac. Dis."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"62","DOI":"10.12659\/AJCR.882757","article-title":"Amiodarone Induced Pulmonary Toxicity: An Unusual Response to Steroids","volume":"13","author":"Garg","year":"2012","journal-title":"Am. J. Med. Case Rep."},{"key":"ref_103","first-page":"667","article-title":"Severe Amiodarone Induced Pulmonary Toxicity","volume":"4","author":"Nacca","year":"2012","journal-title":"J. Thorac Dis."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s13256-018-1629-8","article-title":"Amiodarone-Induced Reversible and Irreversible Hepatotoxicity: Two Case Reports","volume":"12","author":"Tsuda","year":"2018","journal-title":"J. Med. Case Rep."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"116","DOI":"10.14309\/crj.2015.23","article-title":"Amiodarone-Induced Liver Injury and Cirrhosis","volume":"2","author":"Buggey","year":"2015","journal-title":"ACG Case Rep. J."},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Frenkel, A., Smadar, R., Shiloh, A., Morad, M., Shimoni-Rachmilev, O., and Dreiher, J. (2024). Adherence to Monitoring of Patients Treated with Amiodarone: A Nationwide Study. Front. Med., 11.","DOI":"10.3389\/fmed.2024.1408799"},{"key":"ref_107","first-page":"e27958","article-title":"A Rare Case of Intravenous Amiodarone Toxicity","volume":"14","author":"Lagarto","year":"2022","journal-title":"Cureus"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"40","DOI":"10.14740\/gr1254","article-title":"Concomitant Acute Hepatic Failure and Renal Failure Induced by Intravenous Amiodarone: A Case Report and Literature Review","volume":"13","author":"Mohamed","year":"2020","journal-title":"Gastroenterol. Res."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1097\/01.CCM.0000151048.72393.44","article-title":"Hepatotoxicity during Rapid Intravenous Loading with Amiodarone: Description of Three Cases and Review of the Literature*","volume":"33","author":"Bravo","year":"2005","journal-title":"Crit. Care Med."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.bcp.2010.11.002","article-title":"The Role of CYP3A4 in Amiodarone-Associated Toxicity on HepG2 Cells","volume":"81","author":"Zahno","year":"2011","journal-title":"Biochem. Pharmacol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"196","DOI":"10.4254\/wjh.v4.i6.196","article-title":"Acute Hepatitis Secondary to Parenteral Amiodarone Does Not Preclude Subsequent Oral Therapy","volume":"4","author":"Lahbabi","year":"2012","journal-title":"World J. Hepatol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1136\/gut.34.4.565","article-title":"Early Acute Hepatitis with Parenteral Amiodarone: A Toxic Effect of the Vehicle?","volume":"34","author":"Rhodes","year":"1993","journal-title":"Gut"},{"key":"ref_113","first-page":"189","article-title":"Hepatotoxicity after Continuous Amiodarone Infusion in a Postoperative Cardiac Infant","volume":"17","author":"Kicker","year":"2012","journal-title":"J. Pediatr. Pharmacol. Ther."},{"key":"ref_114","first-page":"233","article-title":"Severe Acute Hepatitis Following Intravenous Amiodarone: A Case Report and Review of the Literature","volume":"78","author":"Stratton","year":"2015","journal-title":"Acta Gastro-Enterol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1124\/jpet.106.108993","article-title":"Hepatocellular Toxicity and Pharmacological Effect of Amiodarone and Amiodarone Derivatives","volume":"319","author":"Waldhauser","year":"2006","journal-title":"J. Pharmacol. Exp."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"e260","DOI":"10.1097\/MJT.0000000000000149","article-title":"Acute Hepatotoxicity of Intravenous Amiodarone","volume":"23","author":"Chen","year":"2016","journal-title":"Am. J. Ther."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.tcm.2018.09.005","article-title":"Amiodarone and Thyroid Physiology, Pathophysiology, Diagnosis and Management","volume":"29","author":"Trohman","year":"2019","journal-title":"Trends Cardiovasc. Med."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1097\/MED.0000000000000562","article-title":"Thyroid Effects of Amiodarone: Clinical Update","volume":"27","author":"Goundan","year":"2020","journal-title":"Curr. Opin. Endocrinol. Diabetes. Obes."},{"key":"ref_119","first-page":"240","article-title":"The Effects of Amiodarone on the Thyroid","volume":"22","author":"Martino","year":"2001","journal-title":"Endocr. Rev."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.amjmed.2004.11.028","article-title":"Amiodarone and the Thyroid","volume":"118","author":"Basaria","year":"2005","journal-title":"Am. J. Med."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"136","DOI":"10.23736\/S0026-4806.17.04923-0","article-title":"Effect of Excess Iodine Intake on Thyroid on Human Health","volume":"108","author":"Koukkou","year":"2017","journal-title":"Minerva Med."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.tcm.2022.01.001","article-title":"Prevalence of Amiodarone-Induced Hypothyroidism; a Systematic Review and Meta-Analysis","volume":"33","author":"Mohammadi","year":"2022","journal-title":"Trends Cardiovasc. Med."},{"key":"ref_123","first-page":"34","article-title":"Effects of Amiodarone Therapy on Thyroid Function","volume":"6","author":"Dahl","year":"2009","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_124","first-page":"269","article-title":"Amiodarone-Induced Thyroid Dysfunction in Clinical Practice","volume":"10","author":"Ursella","year":"2006","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.12968\/hmed.2023.0214","article-title":"Monitoring Thyroid Function during Amiodarone Use","volume":"85","author":"Sharma","year":"2024","journal-title":"Br. J. Hosp. Med."},{"key":"ref_126","first-page":"2690","article-title":"Prevalence of Amiodarone-Induced Hypothyroidism and Hyperthyroidism in Patients with Heart Diseases: A Systematic Review and Meta-Analysis","volume":"29","author":"Johnston","year":"2022","journal-title":"Curr. Med. Chem."},{"key":"ref_127","first-page":"e40893","article-title":"Amiodarone-Induced Myxedema Coma in Elderly Patients: A Systematic Review of Case Reports","volume":"15","author":"Alnaeem","year":"2023","journal-title":"Cureus"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.5114\/aoms.2013.35026","article-title":"Letter to the Editor Amiodarone-Induced Myxedema Coma\u2014A Case and Review of the Literature","volume":"6","author":"Chakraborty","year":"2014","journal-title":"Arch. Med. Sci."},{"key":"ref_129","first-page":"bcr2013202338","article-title":"Amiodarone-Induced Myxoedema Coma","volume":"2014","author":"Hassan","year":"2014","journal-title":"Case Rep."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.ando.2018.05.001","article-title":"Issues in Amiodarone-Induced Thyrotoxicosis: Update and Review of the Literature","volume":"80","author":"Maqdasy","year":"2019","journal-title":"Ann. Endocrinol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.ando.2024.01.006","article-title":"Amiodarone-Induced Thyrotoxicosis: Should Surgery Be Considered?","volume":"85","author":"Frey","year":"2024","journal-title":"Ann. Endocrinol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"e238145","DOI":"10.1136\/bcr-2020-238145","article-title":"Amiodarone-Induced Type 2 Thyrotoxicosis","volume":"14","author":"Portelli","year":"2021","journal-title":"BMJ Case Rep."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.36660\/abc.20190757","article-title":"Tireotoxicose Induzida Pela Amiodarona\u2014Revis\u00e3o de Literatura E Atualiza\u00e7\u00e3o Cl\u00ednica","volume":"117","author":"Campagnolo","year":"2021","journal-title":"Arq. Bras. Cardiol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"210529","DOI":"10.1155\/2012\/210529","article-title":"A Risk Prediction Index for Amiodarone-Induced Thyrotoxicosis in Adults with Congenital Heart Disease","volume":"2012","author":"Stan","year":"2012","journal-title":"J. Thyroid Res."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.ijcard.2012.02.015","article-title":"Body Mass Index and the Development of Amiodarone-Induced Thyrotoxicosis in Adults with Congenital Heart Disease\u2014A Cohort Study","volume":"167","author":"Stan","year":"2013","journal-title":"Int. J. Cardiol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1089\/thy.2021.0055","article-title":"Effects of Thyroid Function on Hemostasis, Coagulation, and Fibrinolysis: A Mendelian Randomization Study","volume":"31","author":"Ellervik","year":"2021","journal-title":"Thyroid"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"e230254","DOI":"10.1530\/ETJ-23-0254","article-title":"Epidemiology, Prognosis and Challenges in the Management of Hyperthyroidism-Related Atrial Fibrillation","volume":"13","author":"Kostopoulos","year":"2024","journal-title":"Eur. Thyroid J."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.4158\/EP13093.RA","article-title":"Effects of Amiodarone, Thyroid Hormones and CYP2C9 and VKORC1 Polymorphisms on Warfarin Metabolism: A Review of the Literature","volume":"19","author":"Tomisti","year":"2013","journal-title":"Endocr. Pract."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1159\/000486957","article-title":"2018 European Thyroid Association (ETA) Guidelines for the Management of Amiodarone-Associated Thyroid Dysfunction","volume":"7","author":"Bartalena","year":"2018","journal-title":"Eur. Thyr. J."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"e1006","DOI":"10.1210\/clinem\/dgz292","article-title":"Prospective Trial of Functional Thyrotropin Receptor Antibodies in Graves Disease","volume":"105","author":"Kahaly","year":"2019","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S0828-282X(09)70512-4","article-title":"Amiodarone-Induced Thyrotoxicosis: A Review","volume":"25","author":"Tsang","year":"2009","journal-title":"Can. J. Cardiol."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"e582","DOI":"10.1097\/RLU.0000000000004332","article-title":"99mTc-Sestamibi Thyroid Scintigraphy in Amiodarone-Induced Thyrotoxicosis","volume":"47","author":"Wang","year":"2022","journal-title":"Clin. Nucl. Med."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"176","DOI":"10.5603\/EP.2015.0025","article-title":"Amiodaron I Tarczyca","volume":"66","author":"Bednarczuk","year":"2015","journal-title":"Endokrynol. Pol."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.ecl.2007.06.002","article-title":"Hyperthyroidism","volume":"36","author":"Nayak","year":"2007","journal-title":"Endocrinol. Metab. Clin. N. Am."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"E49","DOI":"10.1210\/jc.2011-2221","article-title":"Antithyroid Drug-Induced Hematopoietic Damage: A Retrospective Cohort Study of Agranulocytosis and Pancytopenia Involving 50,385 Patients with Graves\u2019 Disease","volume":"97","author":"Watanabe","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1210\/jcem-35-6-905","article-title":"The Inhibitory Effect of Lithium on Thyroid Hormone Release in Both Euthyroid and Thyrotoxic Patients","volume":"35","author":"Spaulding","year":"1972","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1177\/0885066613498053","article-title":"Thyroid Storm","volume":"30","author":"Chiha","year":"2013","journal-title":"J. Intensive Care Med."},{"key":"ref_148","first-page":"366","article-title":"Clinical Review and Update on the Management of Thyroid Storm","volume":"119","author":"McCalmon","year":"2022","journal-title":"Mo. Med."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/s12020-008-9107-5","article-title":"Low Doses of Cholestyramine in the Treatment of Hyperthyroidism","volume":"34","author":"Kaykhaei","year":"2008","journal-title":"Endocrine"},{"key":"ref_150","first-page":"2475843","article-title":"Thyroid Storm with Multiorgan Failure Treated with Plasmapheresis","volume":"2019","author":"Miller","year":"2019","journal-title":"Case Rep. Endocrinol."},{"key":"ref_151","first-page":"bcr2012006696","article-title":"Surviving the Storm: Two Cases of Thyroid Storm Successfully Treated with Plasmapheresis","volume":"2012","author":"Carhill","year":"2012","journal-title":"Case Rep."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/S0140-6736(23)02016-0","article-title":"Hyperthyroidism","volume":"403","author":"Chaker","year":"2024","journal-title":"Lancet"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.anorl.2014.04.005","article-title":"Surgical Management of Hyperthyroidism","volume":"132","author":"Germain","year":"2015","journal-title":"Eur. Ann. Otorhinolaryngol. Head Neck Dis."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"327","DOI":"10.7326\/0003-4819-143-5-200509060-00008","article-title":"Amiodarone Prophylaxis Reduces Major Cardiovascular Morbidity and Length of Stay after Cardiac Surgery: A Meta-Analysis","volume":"143","author":"Aasbo","year":"2005","journal-title":"Ann. Intern. Med."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.12659\/MSM.890881","article-title":"Cutaneous Adverse Reactions of Amiodarone","volume":"20","author":"Jaworski","year":"2014","journal-title":"Med. Sci. Monit."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"821","DOI":"10.2165\/11592780-000000000-00000","article-title":"Drug-Induced Photosensitivity","volume":"34","author":"Drucker","year":"2011","journal-title":"Drug Saf."},{"key":"ref_157","first-page":"E11","article-title":"Amiodarone-Related Blue\u2013Gray Skin Discoloration","volume":"21","author":"Barman","year":"2019","journal-title":"Anatol. J. Cardiol."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"101315","DOI":"10.1016\/j.cpcardiol.2022.101315","article-title":"Amiodarone Related Skin Toxicity \u2013the Blue Man Syndrome; a Case Report and Review of Literature","volume":"47","author":"Safdar","year":"2022","journal-title":"Curr. Probl. Cardiol."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1136\/hrt.2006.091462","article-title":"Amiodarone-Induced Skin Pigmentation: Q-Switched Laser Therapy, an Effective Treatment Option","volume":"93","author":"Wiper","year":"2007","journal-title":"Heart"},{"key":"ref_160","first-page":"e57574","article-title":"Drug-Induced Pseudoporphyria: A Case Report","volume":"16","author":"Jangid","year":"2024","journal-title":"Cureus"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"508","DOI":"10.2340\/00015555-3154","article-title":"Drug-Induced Linear IgA Bullous Dermatosis: A Case Report and Review of the Literature","volume":"99","author":"Lammer","year":"2019","journal-title":"Acta Derm. Venereol."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1046\/j.1440-0960.2002.00549.x","article-title":"Two Unusual Cases of Toxic Epidermal Necrolysis","volume":"43","author":"Yung","year":"2002","journal-title":"Aust. J. Dermatol."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.amjmed.2012.12.002","article-title":"A Dire Reaction: Rash after Amiodarone Administration","volume":"126","author":"Chen","year":"2013","journal-title":"Am. J. Med."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1136\/hrt.2005.086157","article-title":"Amiodarone Induced Skin Necrosis","volume":"92","author":"Russell","year":"2006","journal-title":"Heart"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1111\/j.1365-4632.2008.03819.x","article-title":"Amiodarone-Induced Skin Pigmentation and Multiple Basal-Cell Carcinomas","volume":"48","author":"Maoz","year":"2009","journal-title":"Int. J. Dermatol."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1097\/OPX.0000000000001534","article-title":"Ocular Adverse Effects of Amiodarone: A Systematic Review of Case Reports","volume":"97","author":"Alshehri","year":"2020","journal-title":"Optom. Vis. Sci."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1016\/S0161-6420(84)34165-3","article-title":"Clinical Experience and Grading of Amiodarone Keratopathy","volume":"91","author":"Orlando","year":"1984","journal-title":"Ophthalmology"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"258","DOI":"10.4103\/0974-9233.154411","article-title":"Amiodarone-Induced Multiorgan Toxicity with Ocular Findings on Confocal Microscopy","volume":"22","author":"Yilmaz","year":"2015","journal-title":"Middle East Afr. J. Ophthalmol."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1016\/j.ophtha.2016.08.001","article-title":"Corneal Densitometry as a Novel Technique for Monitoring Amiodarone Therapy","volume":"123","author":"Alnawaiseh","year":"2016","journal-title":"Ophthalmology"},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"e000943","DOI":"10.1136\/bmjophth-2021-000943","article-title":"Drug-Induced Corneal Deposits: An Up-To-Date Review","volume":"7","author":"Sahyoun","year":"2022","journal-title":"BMJ Open Ophthalmol."},{"key":"ref_171","doi-asserted-by":"crossref","unstructured":"Mitchell, R., and Chacko, J. (2022). Clinical and Mechanistic Review of Amiodarone-Associated Optic Neuropathy. Biomolecules, 12.","DOI":"10.3390\/biom12091298"},{"key":"ref_172","first-page":"1477","article-title":"The Clinical Spectrum of Amiodarone-Associated Optic Neuropathy","volume":"96","author":"Johnson","year":"2004","journal-title":"J. Natl. Med. Assoc."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.amjmed.2011.09.020","article-title":"Amiodarone-Associated Optic Neuropathy: A Critical Review","volume":"125","author":"Passman","year":"2012","journal-title":"Am. J. Med."},{"key":"ref_174","first-page":"e28412","article-title":"Myoclonic Jerks and Ataxia: A Case of Rare Neurological Side Effects of Amiodarone","volume":"14","author":"Damughatla","year":"2022","journal-title":"Cureus"},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1002\/jcph.2330","article-title":"Amiodarone-Induced Nystagmus and Ataxia: Case Report and Systematic Review of Case Reports","volume":"63","author":"Kaur","year":"2023","journal-title":"J. Clin. Pharmacol."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1007\/s12603-020-1475-4","article-title":"Amiodarone-Induced Ataxia: A Case Report of Severe Cerebellar Dysfunction and Review of Literature","volume":"25","author":"Sarrazin","year":"2020","journal-title":"J. Nutr. Health Aging"},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"104167","DOI":"10.1016\/j.amsu.2022.104167","article-title":"CLInical Profile and Side Effects of Chronic Use of Oral Amiodarone in Cardiology Outpatients Department (CLIPSE-A Study)\u2014A Prospective Observational Study","volume":"80","author":"Fatima","year":"2022","journal-title":"Ann. Med. Surg."},{"key":"ref_178","doi-asserted-by":"crossref","unstructured":"Miernik, S., Matusiewicz, A., and Olesi\u0144ska, M. (2024). Drug-Induced Myopathies: A Comprehensive Review and Update. Biomedicines, 12.","DOI":"10.3390\/biomedicines12050987"},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"e50","DOI":"10.1111\/j.1468-1331.2012.03678.x","article-title":"Amiodarone-Associated Neuromyopathy: A Report of Four Cases","volume":"19","author":"Flanagan","year":"2012","journal-title":"Eur. J. Neurol."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"100929","DOI":"10.1016\/j.eucr.2019.100929","article-title":"Amiodarone Induced Epididymo-Orchitis","volume":"26","author":"Dasu","year":"2019","journal-title":"Urol. Case Rep."},{"key":"ref_181","first-page":"e62861","article-title":"Amiodarone-Induced Epididymitis: A Case Report and Review of the Literature","volume":"16","author":"Lyon","year":"2024","journal-title":"Cureus"},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.amjmed.2015.08.039","article-title":"Practical Management Guide for Clinicians Who Treat Patients with Amiodarone","volume":"129","author":"Epstein","year":"2016","journal-title":"Am. J. Med."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1016\/j.hrthm.2007.07.020","article-title":"A Practical Guide for Clinicians Who Treat Patients with Amiodarone: 2007","volume":"4","author":"Goldschlager","year":"2007","journal-title":"Heart Rhythm"},{"key":"ref_184","unstructured":"NHS Derbyshire Joint Area Prescribing Comittee (2024, August 30). Amiodarone Monitoring Protocol, Available online: https:\/\/www.derbyshiremedicinesmanagement.nhs.uk\/assets\/Clinical_Guidelines\/Formulary_by_BNF_chapter_prescribing_guidelines\/BNF_chapter_2\/Amiodarone_monitoring.pdf."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/20\/6094\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:12:22Z","timestamp":1760112742000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/20\/6094"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,12]]},"references-count":184,"journal-issue":{"issue":"20","published-online":{"date-parts":[[2024,10]]}},"alternative-id":["jcm13206094"],"URL":"https:\/\/doi.org\/10.3390\/jcm13206094","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,12]]}}}